Thromboxane inhibition during concurrent therapy with low-dose aspirin and over-the-counter naproxen sodium
| Autor: | Kevin P. Bliden, Paul A. Gurbel, Robert Centofanti, Udaya S. Tantry, Palak Venkataraman, Junhong Zhu, Sistine Jarvis, Emanuel Troullos |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Male
Naproxen Thromboxane Naproxen Sodium 030204 cardiovascular system & hematology Pharmacology 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Medicine Humans Drug Interactions 030212 general & internal medicine Aspirin Dose-Response Relationship Drug business.industry Anti-Inflammatory Agents Non-Steroidal Thromboxanes Hematology Middle Aged Clinical trial Thromboxane B2 chemistry Pharmacodynamics Platelet aggregation inhibitor Female Cardiology and Cardiovascular Medicine business Platelet Aggregation Inhibitors medicine.drug |
| Zdroj: | Journal of thrombosis and thrombolysis. 45(1) |
| ISSN: | 1573-742X |
| Popis: | Aspirin is the dominant antiplatelet therapy for cardiovascular disease. Naproxen is frequently used in aspirin-treated patients and may influence the antiplatelet effect of aspirin. We evaluated the pharmacodynamic interaction (lower bound of the one-sided 95% CI for serum TxB2 inhibition 98% at all time points. The clinical relevance of these observations remains unknown and merits further investigation since over-the-counter naproxen is widely used to relieve pain by individuals taking low dose aspirin for cardioprotection. Clinical Trial Registration: NCT02229461 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink